Skip to main content
OpenTrials
Completed

NCT Number: NCT01427803

Actual Use Trial of Naproxen Sodium

An actual use trial to demonstrate that consumers will not exceed the labeled daily dose of Aleve 24 Hour at an unacceptable rate. Two aspects of consumer use will be evaluated: 1) the frequency at which consumers exceed the label-defined daily dose, thus putting themselves at clinical risk, and 2) the reasons for exceeding the labeled daily dose.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pain Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hoover, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 12 years of age
  • Report taking OTC analgesics for pain on at least 5 days in the last month
  • Report having had pain at least once in the last 3 months lasting longer than 12 hours or that they believe would have lasted longer than 12 hours if they had not treated it
  • Able to read and understand English
  • Provide written informed consent (subjects 12-17 years of age provide written assent and/or parent or legal guardian provide written consent)
  • Provide contact information
  • Purchase the investigational product

Exclusion criteria

  • Have participated in a trial involving OTC analgesics in the last 6 months
  • They or someone else in the household work for a market research company, an advertising agency, a public relations firm, a pharmaceutical company, as a healthcare professional, or as part of a health care practice (eliminated for reasons of confidentiality or increased awareness of drugs and their labels)
  • Have a history of known allergies to NSAIDs (i.e., naproxen, ibuprofen, aspirin, etc.)
  • Have a history of heart surgery in the last 60 days or plans for heart surgery in the next 60 days
  • (Female subjects) are pregnant or breastfeeding

Treatment and study plan

Naproxen sodium ER (BAYH6689)

Drug

BAYH6689; oral tablet used as needed upon incidence of pain

Primary outcomes

  1. Estimated Percentage of Misuse for Non-Therapeutic Reasons

    Time frame: 28 days

    The primary objective of this trial was to determine the percentage of non-therapeutic misuse. Two aspects of consumer use of Aleve 24 Hour were examined: the frequency at which consumers exceeded the label-defined daily dose modified by those who did so for non-therapeutic reasons.

Secondary outcomes

  1. Non-therapeutic Reasons for Misuse

    Time frame: 28 days

    Those subjects in the Reasons for Misuse Cohort who did not state misuse due to need for additional pain relief were categorized to Non-therapeutic misuse.

  2. Estimated Percentage of Misuse for Non-Therapeutic Reasons Using the First 10-Day Treatment Course

    Time frame: 28 days

    This endpoint was an assessment of whether the rate of non-therapeutic misuse exceeded the pre-defined acceptable threshold for non-therapeutic misuse. The difference lay in the estimation of misuse in the Patterns of Use Cohort by using 10-day treatment courses rather than by "use day". A treatment course for each subject began on the first day they recorded taking one or more tablets which was followed by nine consecutive "evaluable days."

  3. Percentage of Participants Took >/= 2 Tablets/Use Day in Any 10 Use Days

    Time frame: 28 days

    Percentage of participants took >/= 2 tablets/use day in any 10 use days thus exceeding the label directions during a treatment course.

  4. Percentage of Participants Who Took Product With Mean Daily Use >/= 2 Tablets /Use Day

    Time frame: 28 days

    Percentage of participants who took product with mean daily use >/= 2 tablets /use day thus exceeding the label directions on any use day.

  5. Percentage of Participants With at Least One Dosing Occasion Where More Than One Tablet Was Taken

    Time frame: 28 days

    Percentage of participants with at least one dosing occasion where more than one tablet was taken thus exceeding the label directions.

  6. Percentage of Dosing Occasions Where More Than One Tablet Was Taken

    Time frame: 28 days

    Percentage of dosing occasions where more than one tablet was taken thus exceeding the label directions.

  7. Percentage of Participants Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose

    Time frame: 28 days

    Percentage of participants where a dose was taken less than 22 hours after the most recent previous dose thus exceeding the label directions. 22 hrs was chosen to allow for some imprecision in subjects' recollection.

  8. Percentage of Dosing Occasions Where a Dose Was Taken Less Than 22 Hours After the Most Recent Previous Dose

    Time frame: 28 days

    Percentage of dosing occasions where a dose was taken less than 22 hours after the most recent previous dose. 22 hrs was chosen to allow for some imprecision in subjects' recollection

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

An Actual Use Trial In A Simulated OTC Environment of an Extended-Release Over-the-Counter NSAID

Acronym: Kiefer AUT

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Sep 2, 2011
Registry last updated
Oct 15, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.